The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu
Trial record 1 of 1 for:    nxp900
Previous Study | Return to List | Next Study

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05873686
Recruitment Status : Recruiting
First Posted : May 24, 2023
Last Update Posted : May 14, 2024
Information provided by (Responsible Party):
Nuvectis Pharma, Inc.

Brief Summary:
The purpose of this dose escalation study is to evaluate the safety profile of escalating doses and dose schedules of NXP900.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumor Drug: NXP900 Phase 1

Detailed Description:
This is a dose escalation study of NXP900 administered to patients with advanced cancers. The study will propose dose and dose schedules for future studies.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: N/A
Intervention Model: Sequential Assignment
Intervention Model Description: Sequential assignment, dose escalation
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Actual Study Start Date : October 26, 2023
Estimated Primary Completion Date : September 2024
Estimated Study Completion Date : January 2025

Arm Intervention/treatment
Experimental: Dose Escalation
Escalating doses of NXP900 are planned with a starting dose level of 20 mg once per day.
Drug: NXP900
NXP900 is an orally administered SRC/YES1 kinase inhibitor

Primary Outcome Measures :
  1. Number of patients with treatment related adverse events and/or clinical laboratory abnormalities [ Time Frame: Day 28 ]
  2. Number of patients who experience Dose Limiting Toxicities (DLT) as defined in the protocol [ Time Frame: Day 28 ]

Secondary Outcome Measures :
  1. Area under the concentration-time curve (AUC) of NXP900 [ Time Frame: First dose through Day 29 ]
  2. Maximum observed concentration (Cmax) of NXP900 [ Time Frame: First dose through Day 29 ]
  3. Time to peak concentration (Tmax) of NXP900 [ Time Frame: First dose through Day 29 ]
  4. Half-life (T1/2) of NXP900 [ Time Frame: First dose through Day 29 ]
  5. Apparent volume of distribution at steady state (Vss/F) of NXP900 [ Time Frame: First dose through Day 29 ]
  6. Apparent plasma clearance at steady state (Clss/F) of NXP900 [ Time Frame: First dose through Day 29 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Provide written informed consent.
  2. 18 years old or older.
  3. Advanced, metastatic, and/or progressive solid tumors for whom there is no authorized or effective therapy available, or for whom such therapies are considered inappropriate by the Investigator.
  4. Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

Exclusion Criteria:

  1. Subjects with known human epidermal growth factor receptor 2 (HER2+) overexpressing malignancies.
  2. Radiotherapy (except for palliative reasons), endocrine therapy, chemotherapy, or investigational agent within 28 days, (42 days for nitrosoureas, mitomycin-C) of first dose of NXP900. Subjects can continue to receive bisphosphonates due to metastatic bone disease or GnRH agonists if they have prostate cancer.
  3. Ongoing toxic manifestations of previous treatments > Grade 2 with the exception of alopecia and neuropathy.
  4. Subjects with treated brain metastases with evidence of progression within 28 days after central nervous system (CNS)-directed treatment, as ascertained by clinical examination and brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] scan) during the Screening period.
  5. Female subjects who can become pregnant (or are already pregnant or lactating), unless they have a negative serum pregnancy test before enrollment and agree to use at least one highly effective form of contraception .
  6. Male subjects with partners of childbearing potential, unless they agree to take measures not to father children by using a barrier method of contraception (condom plus spermicide).
  7. Major surgery from which the subject has not yet recovered.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05873686

Layout table for location contacts
Contact: Diane Marsolini (201) 627-8154
Contact: Shay Shemesh (201) 614-3153

Layout table for location information
United States, Arizona
Mayo Clinic Recruiting
Phoenix, Arizona, United States, 85054
Contact    855-776-0015      
United States, Colorado
Sarah Cannon Research Institute at HealthONE Recruiting
Denver, Colorado, United States, 80218
Contact    720-754-2610      
United States, Florida
Mayo Clinic Recruiting
Jacksonville, Florida, United States, 32224
Contact    855-776-0015      
United States, Oregon
Oregon Health and Science University Recruiting
Portland, Oregon, United States, 97239
Contact    503-494-6865      
United States, Texas
The University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Jordi Rodon Ahnert, MD, PhD    713-792-5603      
United Kingdom
Ward 1 - Edinburgh Cancer Centre, Western General Hospital Recruiting
Edinburgh, United Kingdom, EH4 2XU
Contact: Christen Lauder    0131 537 1265   
The Royal Marsden NHS Foundation and Trust Recruiting
London, United Kingdom, SW3 6JJ
Sponsors and Collaborators
Nuvectis Pharma, Inc.
Layout table for investigator information
Principal Investigator: Udai Banerji, Prof Institute of Cancer Research, Royal Marsden NHS Foundation Trust
Layout table for additonal information
Responsible Party: Nuvectis Pharma, Inc. Identifier: NCT05873686    
Other Study ID Numbers: NXP900-101
First Posted: May 24, 2023    Key Record Dates
Last Update Posted: May 14, 2024
Last Verified: October 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Nuvectis Pharma, Inc.:
Solid Tumor